| Dr John James Openshaw, MD | |
|
111 Colchester Ave, Burlington, VT 05401-1473 | |
| (802) 847-0000 | |
| Not Available |
| Full Name | Dr John James Openshaw |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 16 Years |
| Location | 111 Colchester Ave, Burlington, Vermont |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679720460 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | A109301 (California) | Secondary |
| 207RI0200X | Internal Medicine - Infectious Disease | 042.0016401 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Univ. Of Vermont - Fletcher Allen Health Care | Burlington, VT | Hospital |
| San Mateo Medical Center | San mateo, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| County Of San Mateo | 9032023171 | 242 |
| University Of Vermont Medical Center Inc | 3779491071 | 994 |
News Archive
Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s.
BrainStorm Cell Therapeutics Inc., a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of "NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results," in the international, peer-reviewed journal Neurology.
AARP and the Philadelphia Department of Recreation will be hosting an outdoor Health and Wellness event on Monday June 20, 2011 from 12:00 pm- 2:00 pm at Love Park in Center City Philadelphia.
Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).
› Verified 8 days ago
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s.
BrainStorm Cell Therapeutics Inc., a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of "NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results," in the international, peer-reviewed journal Neurology.
AARP and the Philadelphia Department of Recreation will be hosting an outdoor Health and Wellness event on Monday June 20, 2011 from 12:00 pm- 2:00 pm at Love Park in Center City Philadelphia.
Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).
› Verified 8 days ago
| Entity Name | County Of San Mateo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679642326 PECOS PAC ID: 9032023171 Enrollment ID: O20031126000292 |
News Archive
Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s.
BrainStorm Cell Therapeutics Inc., a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of "NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results," in the international, peer-reviewed journal Neurology.
AARP and the Philadelphia Department of Recreation will be hosting an outdoor Health and Wellness event on Monday June 20, 2011 from 12:00 pm- 2:00 pm at Love Park in Center City Philadelphia.
Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).
› Verified 8 days ago
| Entity Name | County Of San Mateo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831268580 PECOS PAC ID: 9032023171 Enrollment ID: O20040123000822 |
News Archive
Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s.
BrainStorm Cell Therapeutics Inc., a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of "NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results," in the international, peer-reviewed journal Neurology.
AARP and the Philadelphia Department of Recreation will be hosting an outdoor Health and Wellness event on Monday June 20, 2011 from 12:00 pm- 2:00 pm at Love Park in Center City Philadelphia.
Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).
› Verified 8 days ago
| Entity Name | County Of San Mateo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306907928 PECOS PAC ID: 9032023171 Enrollment ID: O20040416001479 |
News Archive
Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s.
BrainStorm Cell Therapeutics Inc., a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of "NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results," in the international, peer-reviewed journal Neurology.
AARP and the Philadelphia Department of Recreation will be hosting an outdoor Health and Wellness event on Monday June 20, 2011 from 12:00 pm- 2:00 pm at Love Park in Center City Philadelphia.
Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John James Openshaw, MD 111 Colchester Ave, Burlington, VT 05401-1473 Ph: (802) 847-0000 | Dr John James Openshaw, MD 111 Colchester Ave, Burlington, VT 05401-1473 Ph: (802) 847-0000 |
News Archive
Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s.
BrainStorm Cell Therapeutics Inc., a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of "NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results," in the international, peer-reviewed journal Neurology.
AARP and the Philadelphia Department of Recreation will be hosting an outdoor Health and Wellness event on Monday June 20, 2011 from 12:00 pm- 2:00 pm at Love Park in Center City Philadelphia.
Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).
› Verified 8 days ago
Nadia Ghallab, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Beach Conger, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 617 Riverside Ave, Burlington, VT 05401 Phone: 802-864-6309 Fax: 802-860-4313 | |
Dr. Christopher Dwight Huston, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-2264 | |
Beth Diane Kirkpatrick, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Fletcher Allen Health Care, Burlington, VT 05401 Phone: 802-847-4594 | |
Dr. Richard Frank Branda, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 1 S. Prospect St, Burlington, VT 05401 Phone: 802-847-3827 Fax: 802-847-3510 | |
Lauren Suggs, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Magdalena Anna Zeglin, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 |